An Open Label Study to Determine ADME of [14C] labeled SLV334 and its Metabolites after Single Intravenous Dose Infusion.

Completed

• Conditions: Traumatische hersenbeschadiging; Brain injury; Therapy

• Registration Number: NL-OMON34670
• Lead Sponsor: Solvay Pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

- Healthy male
- 18-55 years of age, inclusive
- BMI 18.0 - 28.0 kg/m2 (weight between 50 and 100 kg inclusive)
- non-smoker

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Radiodynamics<br /><br>Pharmacokinetics<br /><br>Safety</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>